Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)
Financial Results:
Aurobindo Pharma Ltd reported Revenues for Q3FY25 of ₹7,979.00 Crores up from ₹7,352.00 Crore year on year, a rise of 8.53%.
Total Expenses for Q3FY25 of ₹6,938.00 Crores up from ₹6,252.00 Crores year on year, a rise of 10.97%.
Consolidated Net Profit of ₹846.00 Crores down 10.0% from ₹940.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹14.44, down 9.64% from ₹15.98 in the same quarter of the previous year.
![](data:image/svg+xml;charset=utf-8,<svg height="781px" width="640px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
